All In Biotech

NDA 022462 · Piramal Critical

Gablofen

Baclofen · Intrathecal · gamma-Aminobutyric Acid-ergic Agonist

Last checked: Nov 20, 2026Latest source record: May 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Nov 19, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

123

30 Phase 3, 6 recruiting

FAERS reports

3,114

1,575 serious, 121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

BOXED WARNING WARNING: DO NOT DISCONTINUE ABRUPTLY Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death. Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g., spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal...

What it is approved for

From the label in effect May 7, 2026.

GABLOFEN is indicated for use in the management of severe spasticity in adult and pediatric patients age 4 years and above. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of GABLOFEN via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. GABLOFEN is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only with the Medtronic SynchroMed ® Programmable Pump or other pumps labeled for intrathecal administration of GABLOFEN [see Clinical Studies (14)] . Prior to implantation of a device for chronic intrathecal infusion of GABLOFEN, patients must show a response to GABLOFEN in a screening trial [see Dosage and Administration (2.2)] . GABLOFEN is a gamma-aminobutyric acid (GABA) ergic agonist indicated for use in the management of severe spasticity of cerebral or spinal origin in adult and pediatric patients age 4 years and above. ( 1 ) GABLOFEN should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable central nervous system side effects at effective doses. ( 1 ) Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. ( 1 ) Spasticity due to traumatic brain injury: wait at least one year after injury before considering GABLOFEN therapy. (...

Mechanism: The precise mechanism of action of baclofen as a muscle relaxant and antispasticity agent is not fully understood. Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level, possibly by decreasing excitatory neurotransmitter release from primary afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Baclofen is a structural analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and may exert its effects by stimulation of the GABAB receptor subtype. Baclofen when introduced directly into the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • GABLOFEN · BACLOFEN 1MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
  • GABLOFEN · BACLOFEN 0.5MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
  • GABLOFEN · BACLOFEN 2MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
  • GABLOFEN · BACLOFEN 0.05MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Baclofen" as an intervention, any sponsor and status, largest first.

All 123 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • muscle spasticity771
  • withdrawal syndrome421
  • device issue376
  • drug ineffective294
  • drug withdrawal syndrome272
  • overdose172
  • implant site infection166
  • infection164
  • hypertonia158
  • pruritus157
  • device failure154
  • device malfunction151

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20113
201215
2013333
2014243
2015318
2016145
2017139
2018684
201942
2020247
2021203
2022269
2023170
2024120
2025121
202662

Recalls

1 FDA enforcement reports for this application.

  • Jul 8, 2019 · Class II · Terminated

    Failed Impurities/Degradation Specification -This recall is being initiated as a precaution due to the presence of an unknown impurity observed during shelf life of the product.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gablofen (Baclofen)

2024 spending

$131K

Beneficiaries

34

108 claims

Per beneficiary

$3,858

$42.73 per unit

View as table
YearSpending
2020$109,598
2021$82,815
2022$90,380
2023$108,008
2024$131,171

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 558 on PubMed

Sponsor: Piramal Critical

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.